1. Supplementary Table. Gene expression profiling reveals a decrease in NFkB-driven gene signature pattern upon treatment with MLN4924.
Gene ID
Name
Treated/
untreated fold ratio
P value
BCL2L1 (Bcl-xL)
BCL2-like 1, nuclear gene encoding mitochondrial protein, transcript variant 1
0.51
0.0008
BCL2
B-cell CLL/lymphoma 2, nuclear gene encoding mitochondrial protein, transcript variant alpha
0.66
0.02
BCL2L11 (Bim)
BCL2-like 11 (apoptosis facilitator) (BCL2L11), transcript variant 6
1.96
CCND1
Homo sapiens cyclin D1
0.29
GADD45B
Growth arrest and DNA-damage-inducible, beta
0.34
CCND2
Homo sapiens cyclin D2
0.45
0.0003
STAT5A
Signal transducer and activator of transcription 5A
0.58
CCL22
Chemokine ligand 22
0.06
CXCL9
Chemokine (C-X-C motif) ligand 9
0.27
0.004
CD40
CD40 molecule, TNF receptor superfamily member 5, transcript variant 2
0.41
CD74
CD74 molecule, major histocompatibility complex, class II invariant chain, transcript variant 1
0.42
CXCR7
Chemokine (C-X-C motif) receptor 7
0.43
0.002
CCL5
Chemokine ligand 5
CCL17
Chemokine ligand 17
0.49
CXCR3
Chemokine (C-X-C motif) receptor 3
0.64
0.003
CXCR5
Chemokine (C-X-C motif) receptor 5
0.81
0.04
MIR155HG
MIR155 host gene (non-protein coding)
0.11